Background
Methods
Study population
Patient variables analyzed
Immunohistochemistry methods
Measurement of IMVD
Evaluation of VEGF
Statistical analysis
Results
Clinico-pathological features of RMS patients
Pt | Age (mos) | Gender | Histology | Primary site | Primary size (cm) | Metastasis | Nodes | IRSa Group | COG Risk Groups | EpSSG Risk Groups | Status | CD105/CD31 ratio |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 83 | M | ARMS | Extremity | > 5 | No | N0 | III | Intermediate | HR/G | NED | 1.1611 |
2 | 65 | F | ERMS | Pelvis | > 5 | No | N1 | III | Intermediate | HR/F | NED | 0.6825 |
3 | 43 | M | ERMS | Abdomen | > 5 | No | N0 | III | Intermediate | HR/E | NED | 0.7466 |
4 | 82 | F | ARMS | Extremity | > 5 | No | N0 | III | Intermediate | HR/G | NED | 1.0460 |
5 | 55 | M | ERMS | GU non BP | ≤ 5 | No | N0 | I | Low | LR | NED | 1.4292 |
6 | 41 | M | ERMS | Orbit | > 5 | Bone/BM | N0 | IV | High | META | DOD | 0.5133 |
7 | 28 | F | ARMS | HN PM | ≤ 5 | No | N0 | II | Intermediate | HR/G | NED | 1.4225 |
8 | 13 | M | ARMS | Orbit | ≤ 5 | No | N0 | III | Intermediate | HR/G | NED | 1.7949 |
9 | 11 | F | ERMS | HN PM | ≤ 5 | No | N1 | III | Intermediate | HR/F | DOD | 1.3006 |
10 | 37 | F | ERMS | GU non BP | ≤ 5 | No | N0 | III | Low | SR/C | NED | 0.8942 |
11 | 116 | F | ERMS | Pelvis | > 5 | Lung | Nx | IV | High | META | DOD | 1.0158 |
12 | 176 | M | ARMS | Retroperitoneum | > 5 | Lung | N1 | IV | High | META | DOD | 1.5517 |
13 | 48 | F | ERMS | GU BP | > 5 | No | N0 | III | Intermediate | HR/E | NED | 1.8627 |
14 | 49 | F | ARMS | HN PM | > 5 | No | N1 | III | Intermediate | VERY HR | NED | 1.2461 |
15 | 17 | M | ARMS | HN non PM | ≤ 5 | No | N0 | II | Intermediate | HR/G | NED | 1.0354 |
16 | 1 | M | ERMS | Pelvis | > 5 | No | N0 | II | Low | HR/E | NED | 0.8868 |
17 | 1 | F | ARMS | HN PM | ≤ 5 | Multipleb | N1 | IV | High | META | DOD | 1.5608 |
18 | 16 | F | ARMS | Chest wall | ≤ 5 | No | N0 | II | Intermediate | HR/G | NED | 0.8651 |
19 | 24 | M | ARMS | Orbit | ≤ 5 | No | N0 | III | Intermediate | HR/G | DOD | 2.0024 |
20 | 135 | M | ARMS | Chest wall | > 5 | No | N1 | III | Intermediate | VERY HR | DOD | 1.9190 |
21 | 26 | F | ERMS | Biliary tracts | ≤ 5 | No | N0 | III | Low | SR/D | NED | 1.1058 |
22 | 97 | M | ERMS | Orbit | > 5 | No | N0 | III | Low | SR/C | NED | 1.0274 |
23 | 154 | M | ERMS | Orbit | > 5 | No | N0 | II | Low | SR/C | AWD | 0.9020 |
24 | 14 | F | ERMS | Abdomen | > 5 | No | N1 | I | Low | HR/F | DOD | 2.3542 |
25 | 23 | F | ERMS | Pelvis | > 5 | Lung/Bone | N1 | IV | High | META | NED | 0.7117 |
26 | 199 | F | ERMS | HN PM | > 5 | No | N0 | III | Intermediate | HR/E | AWD | 0.9333 |
27 | 176 | M | ARMS | GU non BP | ≤ 5 | Bone | N1 | IV | High | VERY HR | NED | 0.5914 |
28 | 106 | F | ERMS | HN PM | > 5 | No | N1 | III | Intermediate | HR/F | AWD | 1.0217 |
29 | 146 | M | ERMS | HN non PM | > 5 | No | N1 | III | Low | HR/F | AWD | 0.7733 |
30 | 189 | M | ERMS | Extremity | > 5 | No | N0 | III | Intermediate | HR/E | AWD | 0.3281 |
The ratio of IMVD-CD105 to IMVD-CD31 in RMS primary samples
Correlation between prognostic factors and outcome in RMS patients
Variables | EFS | OS | ||||
---|---|---|---|---|---|---|
Hazard ratio | IC (95%) | P | Hazard ratio | IC (95%) | P | |
Age at diagnosis | ||||||
≥ 1 < 10 (ref) | – | – | – | – | – | – |
< 1 ≥ 10 | 2.58 | 0.78;8.53 | 0.121 | 3.02 | 0.74; 12.25 | 0.121 |
Histology | ||||||
ARMS (ref) | – | – | – | – | – | – |
ERMS | 0.63 | 0.19; 2.06 | 0.443 | 0.86 | 0.21; 3.46 | 0.831 |
Tumor size | ||||||
≤ 5 cm (ref) | – | – | – | – | – | – |
> 5 cm | 1.66 | 0.44;6.28 | 0.453 | 2.17 | 0.43; 10.87 | 0.344 |
Primary site (location) | ||||||
Favorable (ref) | – | – | – | – | – | – |
Unfavorable | 1.11 | 0.32;3.80 | 0.867 | 1.14 | 0.27; 4.80 | 0.851 |
COG Group | ||||||
Low (ref) | – | – | – | – | – | – |
Intermediate | 2.93 | 0.35;24.41 | 0.319 | 1.13 | 011; 10.98 | 0.914 |
High | 9.76 | 1.04;91.19 |
0.046
| 11.59 | 1.19; 112.25 |
0.034
|
VEGF score | ||||||
1–2 (ref) | – | – | – | – | – | – |
3–4 | 0.54 | 0.14;2.06 | 0.373 | 0.46 | 0.93; 2.31 | 0.349 |
CD105/CD31 Ratio | ||||||
< 0.9 (ref) | – | – | – | – | – | – |
≥ 0.9 | 5.31 | 0.75;46.25 | 0.090 | – | – |
–
|
CD105/CD31 Ratio | ||||||
< 1.3 (ref) | – | – | – | – | – | – |
≥ 1.3 | – | – | – | 5.89 | 1.18;29.2 |
0.030
|
Relationship of CD105/CD31 expression ratio with clinico-pathological characteristics and outcome
Variables | Number of patients (%) | Univariable Analysis | ||
---|---|---|---|---|
Coefficient | IC | P value | ||
≥ 1 < 10 (ref) | 21 (70) | – | – | – |
< 1 ≥ 10 | 9 (30) | − 0.10 | − 0.77;0.56 | 0.757 |
Histology | ||||
ARMS (ref) | 12 (40) | – | – | – |
ERMS | 18 (60) | − 0.49 | − 0.89;-0.08 |
0.019
|
Tumor size | ||||
≤ 5 cm (ref) | 10 (33) | – | – | – |
> 5 cm | 20 (77) | − 0.28 | − 0.83;0.27 | 0.313 |
Primary site (location) | ||||
Favorable (ref) | 12 (40) | – | – | – |
Unfavorable | 18 (60) | 0.01 | − 0.45;0.47 | 0.962 |
COG Risk Group | ||||
Low (ref) | 8 (27) | – | – | – |
Intermediate | 16 (53) | 0.13 | − 0.53;0.79 | 0.682 |
High | 6 (20) | − 0.01 | − 0.84;0.81 | 0.977 |
VEGF score | ||||
1–2 (ref) | 19 (63) | – | – | – |
3–4 | 11 (37) | 0.41 | − 0.04;0.85 | 0.072 |
Status | ||||
Alive (ref) | 22 (73) | – | – | – |
Dead | 8 (27) | 0.53 | 0.10; 0.95 |
0.016
|